Ceritinib ALK Inhibitor for Metastatic NSCLC | WHO-GMP

What Is Ceritinib and What Is It Used For?

Ceritinib is a targeted oral therapy classified as a multikinase inhibitor. It is specifically indicated for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors carry anaplastic lymphoma kinase (ALK)-positive mutations. This genetic distinction makes it suitable for a defined patient population with advanced lung cancer. The FDA granted accelerated approval for ceritinib in 2014 as a second-line therapy for patients with ALK-positive metastatic NSCLC whose disease had progressed on or who were intolerant of crizotinib, establishing its role in the treatment landscape for this molecularly defined patient population based on clinical trial evidence demonstrating efficacy.

Unlike traditional chemotherapy, this treatment works by selectively blocking abnormal ALK signaling that drives tumor growth. Therefore, it is considered a precision medicine approach. Patients with confirmed ALK-positive tumors are the primary candidates for this therapy. According to official prescribing information, ALK testing using an FDA-approved diagnostic test is required to identify appropriate candidates for treatment.

The medication is available as a 150 mg oral capsule, with a recommended dose of 750 mg daily — equivalent to five capsules taken together. Its oral administration offers a practical advantage for patients managing long-term treatment regimens. The dosing regimen is based on pharmacokinetic studies and clinical trials that established the therapeutic dose range for optimal efficacy and tolerability.

Cerixen is the Bangladeshi-manufactured generic form of ceritinib, produced by Everest Pharmaceuticals Ltd., a company that operates in compliance with WHO-GMP standards. This quality-assured manufacturing background supports reliable access to the treatment for patients and healthcare providers. Cerixen represents a trusted, locally produced option within the ALK-positive metastatic NSCLC treatment landscape, manufactured according to internationally recognized pharmaceutical quality standards.

How Ceritinib Works: ALK Inhibition Explained

Targeting the ALK Protein Directly

Ceritinib belongs to a class of agents known as multikinase inhibitors. It works by directly targeting the anaplastic lymphoma kinase (ALK) protein, which drives tumor growth in certain lung cancers. When the ALK gene undergoes abnormal fusion, it produces a continuously active protein. This protein sends uncontrolled signals that tell cancer cells to grow and divide. The mechanism of action, as described in official product monographs, involves selective inhibition of ALK tyrosine kinase activity and ALK fusion proteins.

Blocking Abnormal Gene Fusion Activity

In ALK-positive NSCLC, the rearranged ALK gene generates a faulty fusion protein. This medication binds to and blocks that aberrant protein, disrupting the signaling cascade responsible for tumor proliferation. By silencing this specific driver, the treatment effectively cuts off a key mechanism cancer cells depend on for survival. Clinical studies supporting FDA approval demonstrated that this targeted inhibition results in measurable tumor response in patients with ALK-positive metastatic NSCLC.

How This Differs From Traditional Chemotherapy

Conventional chemotherapy broadly attacks dividing cells throughout the body. This therapy, however, takes a fundamentally different approach. It selectively inhibits a defined molecular target — the ALK fusion protein — rather than indiscriminately damaging healthy tissue. This precision-based mechanism represents a significant advance in targeted oncology. Furthermore, it allows clinicians to match therapy specifically to patients whose tumors carry the ALK-positive mutation, as confirmed through validated diagnostic testing methods approved by regulatory authorities.

Cerixen: Ceritinib 150mg Capsules from Bangladesh

Cerixen is a Bangladeshi-manufactured formulation of Ceritinib, developed specifically for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). It is produced by Everest Pharmaceuticals Ltd., a Bangladesh-based manufacturer operating under WHO-GMP compliant standards. This compliance ensures that every batch meets internationally recognized quality benchmarks for oncology medications. WHO-GMP certification indicates adherence to Good Manufacturing Practice guidelines established by the World Health Organization, providing assurance of consistent manufacturing quality and process controls.

Formulation and Dosage Strength

Cerixen is available as a 150mg oral capsule, making it straightforward to administer in outpatient and clinical settings. The recommended therapeutic dose is 750mg daily, achieved by taking five capsules at once. This once-daily oral regimen supports patient adherence without the complexity of intravenous administration. The 150 mg capsule strength reflects the original dosage form of ceritinib; however, the FDA-approved dosage for the originator product Zykadia was subsequently updated to 450 mg tablets taken with food, which should be considered when comparing dosing across different formulations of ceritinib.

Why Source Cerixen from Bangladesh?

Everest Pharmaceuticals Ltd. operates its facility in alignment with WHO-GMP manufacturing protocols. Therefore, healthcare institutions and procurement teams can depend on consistent product quality and supply reliability. Additionally, sourcing a locally manufactured brand like Cerixen supports access to a quality-assured ALK inhibitor without dependence on originator or foreign-manufactured alternatives. This makes it a practical and verifiable option for oncology supply chains serving patients across the region. The WHO-GMP certification provides documented evidence of manufacturing standards that meet international pharmaceutical quality requirements.

Ceritinib vs. Chemotherapy: Targeted Therapy in ALK-Positive NSCLC

A Fundamentally Different Treatment Approach

Ceritinib represents a significant departure from conventional cytotoxic chemotherapy. Traditional chemotherapy attacks rapidly dividing cells indiscriminately, affecting both cancerous and healthy tissue. This medication, available as Cerixen, works through a far more selective mechanism. According to official prescribing information, ceritinib is classified as a kinase inhibitor that specifically targets ALK and other related kinases involved in tumor cell proliferation and survival.

Selective Inhibition of ALK-Positive Cancer Cells

As a multikinase inhibitor, this therapy specifically targets the anaplastic lymphoma kinase (ALK) pathway driving tumor growth. It selectively disrupts signaling in ALK-positive cancer cells, leaving unaffected cells largely undisturbed. Therefore, the treatment acts with far greater precision than broad-spectrum chemotherapy agents. Clinical trial data submitted to the FDA demonstrated that patients with ALK-positive NSCLC experienced tumor response when treated with this targeted agent, validating its mechanism-based approach.

Precision Medicine in Lung Cancer

This approach exemplifies modern precision oncology — matching a treatment directly to a tumor’s genetic profile. Patients with confirmed ALK-positive metastatic NSCLC are identified through biomarker testing before therapy begins. However, this treatment is not appropriate for ALK-negative tumors, underscoring the importance of accurate molecular diagnosis. Additionally, the targeted nature of this therapy reflects a broader global shift toward individualized cancer care over generalized cytotoxic regimens. Regulatory authorities, including the FDA, require confirmation of ALK-positive status using an approved diagnostic test before initiating treatment, as documented in official product labeling.

Packaging and Supply Chain: Cerixen 150mg Capsule Format

Cerixen is formulated as a 150mg oral capsule, a unit size that directly supports efficient bulk procurement and inventory planning. Each capsule represents a discrete, measurable dose unit, simplifying warehouse management and stock rotation for distributors. The 150 mg strength is consistent with the approved dosage form documented in regulatory submissions and official prescribing information for ceritinib products globally.

Daily Dosing Structure and Procurement Planning

The recommended daily dose of 750mg requires five 150mg capsules per administration. This fixed five-capsule structure creates a predictable consumption pattern. Procurement teams can therefore calculate monthly and quarterly order volumes with high accuracy, reducing both stockout risk and excess inventory. The 750 mg daily dose is based on clinical pharmacology studies that established the optimal therapeutic dose for ALK-positive NSCLC, as referenced in FDA-approved prescribing information.

Supply Chain Considerations for International Distributors

For distributors managing oncology portfolios across multiple markets, consistent capsule counts per treatment cycle simplify logistics considerably. The standardized 150mg format integrates smoothly into established cold-chain-free oral oncology distribution workflows. Furthermore, Cerixen is manufactured by Everest Pharmaceuticals Ltd., a Bangladesh-based facility operating in compliance with WHO-GMP standards. This regulatory standing supports market entry documentation across regulated import markets. Additionally, sourcing a WHO-GMP-compliant Bangladeshi brand offers procurement teams a credible, quality-assured alternative within competitive oncology supply frameworks. WHO-GMP certification provides verifiable documentation of manufacturing quality systems that align with international pharmaceutical standards.

Regulatory Context for European Markets

Ceritinib received FDA approval in April 2014, establishing its global clinical credibility as a treatment for ALK-positive metastatic non-small cell lung cancer (NSCLC). This approval milestone signaled to international markets — including European ones — that the therapy met rigorous efficacy and safety standards based on clinical trial evidence. European importers and procurement teams frequently reference FDA approval history when assessing a product’s regulatory standing, as FDA approval provides documented evidence of clinical efficacy and safety evaluation.

However, European markets apply their own compliance frameworks. Importers typically evaluate whether a generic product aligns with EMA-adjacent quality benchmarks and internationally recognized manufacturing standards. Consistency in formulation, documentation, and quality controls plays a decisive role in import decisions. Products manufactured under WHO-GMP standards are generally recognized across multiple regulatory jurisdictions as meeting baseline pharmaceutical quality requirements.

Cerixen, the Bangladeshi-manufactured brand of ceritinib, is produced by Everest Pharmaceuticals Ltd., which operates in compliance with WHO-GMP standards. This certification is directly relevant for European procurement teams. WHO-GMP compliance supports smoother regulatory acceptance across multiple jurisdictions, reducing friction in cross-border supply processes. The WHO-GMP certification provides documented evidence that manufacturing facilities and processes meet internationally recognized quality standards.

Furthermore, sourcing from a WHO-GMP–compliant Bangladeshi manufacturer offers European buyers a traceable, quality-assured supply chain. The 150 mg capsule format — with a recommended oral dose of 750 mg — is consistently produced under these verified standards. This combination of regulatory history and manufacturing compliance makes Cerixen a credible option for European oncology supply networks seeking products manufactured according to internationally recognized pharmaceutical quality guidelines.

B2B Procurement: Sourcing Cerixen for European Distributors

European distributors seeking a dependable supply of Cerixen — the Bangladeshi-manufactured ceritinib formulation for ALK-positive metastatic NSCLC — will find a structured export pathway through our sourcing network. We connect buyers directly with Bangladeshi-origin supply chains, ensuring product authenticity and consistent availability. Our supply channel specializes exclusively in pharmaceutical products manufactured in Bangladesh, providing clear origin documentation and supply chain transparency.

WHO-GMP Compliant Manufacturing Origin

Cerixen is produced in Bangladesh by Everest Pharmaceuticals Ltd., which operates under WHO-GMP standards. This compliance supports regulatory acceptance across multiple international markets. European procurement teams can therefore expect documentation that aligns with stringent import requirements. WHO-GMP certification provides verifiable evidence of manufacturing quality systems, process controls, and facility standards that meet internationally recognized pharmaceutical guidelines.

Export Documentation and Multi-Market Support

Our team provides comprehensive export documentation support, including certificates of origin, product dossiers, and batch-level quality records. Additionally, we accommodate bulk order inquiries with flexible logistics planning suited to multi-country distribution. This makes coordinating cross-border shipments across European territories significantly more efficient. Documentation packages are prepared to support regulatory review processes in destination markets, facilitating smoother customs clearance and import approval procedures.

Enquire About Availability and Bulk Orders

Distributors and hospital procurement departments are encouraged to reach out directly regarding stock availability and volume requirements. We handle inquiries for single-market and multi-market orders alike. Contact our export team to discuss your specific supply timeline and documentation needs for Cerixen 150 mg capsules. Our procurement specialists can provide detailed information on lead times, minimum order quantities, and regulatory documentation requirements for your target markets.

Side Effects of Ceritinib

According to the FDA-approved prescribing information for ceritinib (Zykadia), the most common adverse reactions (reported in at least 25% of patients) include:

• Diarrhea
• Nausea and vomiting
• Fatigue
• Constipation and abdominal pain
• Decreased appetite (anorexia) and weight loss
• Elevated liver enzymes (transaminitis) and hyperglycemia
• Anemia and other laboratory abnormalities

Source: FDA prescribing information for Zykadia (ceritinib). Ceritinib can also cause serious effects including interstitial lung disease (pneumonitis) and QT interval prolongation; patients should consult their oncologist and report new or worsening symptoms immediately.

Frequently Asked Questions About Ceritinib

What condition does Ceritinib treat?

Ceritinib is approved for treating patients with metastatic non-small cell lung cancer (NSCLC) whose tumors carry anaplastic lymphoma kinase (ALK)-positive mutations. This specific genetic marker determines whether a patient qualifies for this therapy. Therefore, ALK testing is an essential step before initiating treatment. According to FDA-approved prescribing information, patients must have ALK-positive disease as detected by an FDA-approved test before starting ceritinib therapy.

How does Ceritinib differ from other ALK inhibitors?

This medication belongs to the multikinase inhibitor class, meaning it targets multiple kinase pathways simultaneously. Additionally, it was developed specifically to address resistance that can emerge with earlier-generation ALK-targeted therapies. Each ALK inhibitor has a distinct resistance profile and tolerability pattern, making clinical differentiation important. Clinical studies documented in regulatory submissions have demonstrated activity in patients who progressed on or were intolerant to prior ALK inhibitor therapy.

Who is eligible for Ceritinib treatment?

The approved patient population includes adults diagnosed with ALK-positive metastatic NSCLC. Patients must undergo confirmed ALK mutation testing before this treatment is considered appropriate. Furthermore, treatment decisions should always be guided by an oncologist familiar with lung cancer molecular profiling. Official prescribing information specifies that ALK-positive status must be confirmed using a validated diagnostic test approved by regulatory authorities before initiating therapy.

Is Cerixen a reliable brand of Ceritinib?

Cerixen is the Bangladeshi-manufactured brand of ceritinib available through our supply network. It is produced by Everest Pharmaceuticals Ltd. under WHO-GMP compliant manufacturing standards, providing quality assurance aligned with internationally recognized pharmaceutical guidelines. It provides patients and healthcare providers access to this targeted therapy through a locally manufactured, quality-assured source. However, suitability for individual patients remains a clinical decision that should be made by qualified healthcare professionals.